Kiniksa(KNSA) - 2024 Q4 - Annual Results

Revenue Performance - ARCALYST net product revenue for 2024 reached $416.4 million, reflecting a 79% year-over-year growth[1] - Kiniksa expects 2025 ARCALYST net product revenue to be between$ 560 million and $580 million[6] - There is substantial opportunity for Kiniksa to drive further ARCALYST revenue through its commercial strategy[2] Patient Engagement - Approximately 13% of the target population of 14,000 multiple-recurrence patients were actively on ARCALYST therapy by the end of 2024[5] - More than 2,850 prescribers have written ARCALYST prescriptions since its launch[5] - The average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months as of the end of Q4 2024[5] Financial Position - Kiniksa had$ 243.6 million in cash, cash equivalents, and short-term investments as of December 31, 2024[11] - Kiniksa anticipates remaining cash flow positive on an annual basis[11] - Kiniksa's financial profile supports the pursuit of additional value-creating opportunities[2] Clinical Development - The company is advancing its clinical portfolio to bring new therapies to patients with unmet medical needs[2]